Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Diseases

  Free Subscription

Articles published in Int J Cancer

Retrieve available abstracts of 59 articles:
HTML format

Single Articles

    July 2022
  1. WEN Q, Chan KH, Shi K, Lv J, et al
    Tobacco smoking and solid fuels for cooking and risk of liver cancer: A prospective cohort study of 0.5 million Chinese adults.
    Int J Cancer. 2022;151:181-190.
    PubMed     Abstract available

    June 2022
  2. NIGER M, Nichetti F, Casadei-Gardini A, Rizzato MD, et al
    Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34182.
    PubMed     Abstract available

  3. ZHENG G, Bouamar H, Cserhati M, Zeballos CR, et al
    Integrin alpha 6 (ITGA6) is upregulated and drives hepatocellular carcinoma progression through integrin alpha6beta4 complex.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34146.
    PubMed     Abstract available

    May 2022
  4. WU H, Zheng X, Pan T, Yang X, et al
    Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34118.
    PubMed     Abstract available

  5. YUN J, Kim YS, Heo MJ, Kim MJ, et al
    ERalpha inhibits mesenchymal and amoeboidal movement of liver cancer cell via Galpha12.
    Int J Cancer. 2022;150:1690-1705.
    PubMed     Abstract available

  6. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
    Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Int J Cancer. 2022;150:1537-1548.
    PubMed     Abstract available

    April 2022
  7. CHEN S, Gao Y, Wang Y, Daemen T, et al
    The Combined Signatures of Hypoxia and Cellular Landscape Provides a Prognostic and Therapeutic Biomarker in HBV-Related Hepatocellular Carcinoma.
    Int J Cancer. 2022 Apr 25. doi: 10.1002/ijc.34045.
    PubMed     Abstract available

  8. LIAO W, Du J, Wang Z, Feng Q, et al
    The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34040.
    PubMed     Abstract available

  9. HEMMINKI K, Tichanek F, Forsti A, Hemminki O, et al
    Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34031.
    PubMed     Abstract available

    March 2022
  10. VAZ J, Midlov P, Eilard MS, Eriksson B, et al
    Targeting population groups with heavier burden of hepatocellular carcinoma incidence: a nationwide descriptive epidemiological study in Sweden.
    Int J Cancer. 2022 Mar 7. doi: 10.1002/ijc.33993.
    PubMed     Abstract available

    February 2022
  11. SEFRIOUI D, Verdier V, Savoye-Collet C, Beaussire L, et al
    Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
    Int J Cancer. 2022;150:532-541.
    PubMed     Abstract available

    December 2021
  12. KIM MN, Han K, Yoo J, Ha Y, et al
    Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study.
    Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33920.
    PubMed     Abstract available

  13. TANAKA H, Horioka K, Hasebe T, Sawada K, et al
    Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor-platelet interactions.
    Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33915.
    PubMed     Abstract available

  14. RUTHERFORD MJ, Arnold M, Bardot A, Ferlay J, et al
    Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
    Int J Cancer. 2021;149:2020-2031.
    PubMed     Abstract available

  15. RIDDER DA, Weinmann A, Schindeldecker M, Urbansky LL, et al
    Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma.
    Int J Cancer. 2021 Dec 11. doi: 10.1002/ijc.33898.
    PubMed     Abstract available

  16. SO R, Chen J, Mehta AJ, Liu S, et al
    Long-term exposure to air pollution and liver cancer incidence in six European cohorts.
    Int J Cancer. 2021;149:1887-1897.
    PubMed     Abstract available

    November 2021
  17. STEPIEN M, Lopez-Nogueroles M, Lahoz A, Kuhn T, et al
    Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
    Int J Cancer. 2021 Nov 29. doi: 10.1002/ijc.33885.
    PubMed     Abstract available

  18. MOEHLER M, Folprecht G, Heinemann V, Holch JW, et al
    Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
    Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.
    PubMed     Abstract available

    September 2021
  19. XU L, Leng C, Chen L, Dong H, et al
    Hypothyroidism is a Predictive Factor of Superior Anti-tumor Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33813.
    PubMed     Abstract available

    August 2021
  20. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    PubMed     Abstract available

    July 2021
  21. CAO M, Huang W, Chen Y, Li G, et al
    Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through beta-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
    Int J Cancer. 2021;149:460-472.
    PubMed     Abstract available

  22. ZHUO Z, Miao L, Hua W, Chen H, et al
    Genetic variations in nucleotide excision repair (NER) pathway genes and hepatoblastoma susceptibility.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33722.
    PubMed     Abstract available

    June 2021
  23. WANG L, Long J, Chen H, Sun S, et al
    Manipulation of focal Wnt activity via synthetic cells in a double-humanized zebrafish model of tumorigenesis.
    Int J Cancer. 2021;148:2815-2824.
    PubMed     Abstract available

    May 2021
  24. LONG L, Liu X, Jin L, Simon T, et al
    Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men.
    Int J Cancer. 2021 May 24. doi: 10.1002/ijc.33699.
    PubMed     Abstract available

    April 2021
  25. MAYEN AL, Aglago EK, Knaze V, Cordova R, et al
    Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: a multinational cohort study.
    Int J Cancer. 2021 Apr 25. doi: 10.1002/ijc.33612.
    PubMed     Abstract available

  26. LU L, Xing K, Wei W, Ling Y, et al
    Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33609.
    PubMed     Abstract available

  27. ZHU HB, Xu D, Ye M, Sun L, et al
    Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
    Int J Cancer. 2021;148:1717-1730.
    PubMed     Abstract available

    March 2021
  28. HUANG C, Fang M, Feng H, Liu L, et al
    N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: a large-scale multicenter study.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33564.
    PubMed     Abstract available

  29. MORISUE R, Kojima M, Suzuki T, Nakatsura T, et al
    Sarcomatoid Hepatocellular Carcinoma is Distinct from Ordinary Hepatocellular Carcinoma: Clinicopathologic, Transcriptomic, and Immunologic Analyses.
    Int J Cancer. 2021 Mar 4. doi: 10.1002/ijc.33545.
    PubMed     Abstract available

  30. WASHINGTON MK, Goldberg RM, Chang GJ, Limburg P, et al
    Diagnosis of digestive system tumours.
    Int J Cancer. 2021;148:1040-1050.
    PubMed     Abstract available

    February 2021
  31. WANG XH, Liu QB, Xiang CL, Mao XH, et al
    Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33516.
    PubMed     Abstract available

  32. XUE M, Lin X, Lin QX, Pu X, et al
    Association between Hepatitis B and E virus infection and hepatocellular carcinoma risk.
    Int J Cancer. 2021 Feb 7. doi: 10.1002/ijc.33505.
    PubMed     Abstract available

    November 2020
  33. WEI R, Zhu WW, Yu GY, Wang X, et al
    S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma.
    Int J Cancer. 2020 Nov 17. doi: 10.1002/ijc.33371.
    PubMed     Abstract available

  34. HEO MJ, Kang SH, Kim YS, Lee JM, et al
    UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
    Int J Cancer. 2020;147:2550-2563.
    PubMed     Abstract available

  35. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    PubMed     Abstract available

    October 2020
  36. LUU HN, Neelakantan N, Geng TT, Wang R, et al
    Quality diet indexes and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33367.
    PubMed     Abstract available

  37. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available

  38. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    PubMed     Abstract available

  39. GERMANOVA D, Keirsse J, Kohler A, Hastir JF, et al
    Myeloid TNF and HO-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
    Int J Cancer. 2020 Oct 10. doi: 10.1002/ijc.33334.
    PubMed     Abstract available

    September 2020
  40. HWANG S, Park YM, Han KD, Yun JS, et al
    Associations of General Obesity and Central Obesity with the Risk of Hepatocellular Carcinoma in a Korean Population: A National Population-Based Cohort Study.
    Int J Cancer. 2020 Sep 21. doi: 10.1002/ijc.33305.
    PubMed     Abstract available

  41. FRENCH B, Sadakane A, Cologne J, Mabuchi K, et al
    Misclassification of primary liver cancer in the Life Span Study of atomic bomb survivors.
    Int J Cancer. 2020;147:1294-1299.
    PubMed     Abstract available

  42. GIANNINI V, Rosati S, Defeudis A, Balestra G, et al
    Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33271.
    PubMed     Abstract available

    August 2020
  43. ZHONG GC, Wang K, Peng Y, Shivappa N, et al
    Dietary inflammatory index and incidence of and death from primary liver cancer: A prospective study of 103,902 American adults.
    Int J Cancer. 2020;147:1050-1058.
    PubMed     Abstract available

  44. FLORIO AA, Campbell PT, Zhang X, Zeleniuch-Jacquotte A, et al
    Abdominal and gluteofemoral size and risk of liver cancer: The liver cancer pooling project.
    Int J Cancer. 2020;147:675-685.
    PubMed     Abstract available

    July 2020
  45. STEPIEN M, Keski-Rahkonen P, Kiss A, Robinot N, et al
    Metabolic perturbations prior to hepatocellular carcinoma diagnosis - Findings from a prospective observational cohort study.
    Int J Cancer. 2020 Jul 31. doi: 10.1002/ijc.33236.
    PubMed     Abstract available

  46. HASSAN SA, Schmithals C, von Harten M, Piiper A, et al
    Time-dependent changes in proliferation, DNA damage and clock gene expression in hepatocellular carcinoma and normal liver of a transgenic mouse model.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33228.
    PubMed     Abstract available

  47. LINDNER AU, Carberry S, Monsefi N, Barat A, et al
    Systems analysis of protein signatures predicting Cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenografts models of metastatic colorectal cancer.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33226.
    PubMed     Abstract available

  48. ZHAO L, Zhang X
    Comments on "One-Carbon Metabolism-Related Micronutrients Intake and Risk for Hepatocellular Carcinoma: A Prospective Cohort Study".
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33184.

  49. ANTWI SO
    Reply to Comments on "One-Carbon Metabolism-Related Micronutrients Intake and Risk for Hepatocellular Carcinoma: A Prospective Cohort Study".
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33186.

    June 2020
  50. OKADA R, Otsuka Y, Wakabayashi T, Shinoda M, et al
    Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: a prospective multicenter study.
    Int J Cancer. 2020 Jun 23. doi: 10.1002/ijc.33165.
    PubMed     Abstract available

    May 2020
  51. GHOSH S, Bhowmik S, Majumdar S, Goswami A, et al
    The Exosome Encapsulated microRNAs as Circulating Diagnostic Marker for Hepatocellular Carcinoma with Low Alpha fetoprotein.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33111.
    PubMed     Abstract available

  52. PETRICK JL, Florio AA, Koshiol J, Pfeiffer RM, et al
    Prediagnostic Concentrations of Circulating Bile Acids and Hepatocellular Carcinoma Risk: REVEAL-HBV and HCV Studies.
    Int J Cancer. 2020 May 13. doi: 10.1002/ijc.33051.
    PubMed     Abstract available

    April 2020
  53. ANTWI SO, Petrick JL, Campbell PT, Norez DA, et al
    One-Carbon Metabolism-Related Micronutrients Intake and Risk for Hepatocellular Carcinoma: A Prospective Cohort Study.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33007.
    PubMed     Abstract available

    February 2020
  54. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    PubMed     Abstract available

  55. XIAO Q, Zhou Y, Winter S, Buttner F, et al
    Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32898.
    PubMed     Abstract available

    January 2020
  56. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    PubMed     Abstract available

    December 2019
  57. WOLSTENHOLME J, Fusco F, Gray AM, Moschandreas J, et al
    Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    Int J Cancer. 2019 Dec 16. doi: 10.1002/ijc.32828.
    PubMed     Abstract available

    October 2019
  58. UMEDA S, Kanda M, Miwa T, Tanaka H, et al
    Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer.
    Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32705.
    PubMed     Abstract available

    September 2019
  59. MIZUKOSHI K, Okazawa Y, Haeno H, Koyama Y, et al
    Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32672.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.